Q3 EPS Estimates for Revolution Medicines Boosted by Wedbush

Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Stock analysts at Wedbush raised their Q3 2025 earnings per share (EPS) estimates for Revolution Medicines in a report issued on Tuesday, June 24th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of $0.12 per share for the quarter, up from their prior forecast of ($1.21). Wedbush currently has a "Outperform" rating and a $73.00 price objective on the stock. The consensus estimate for Revolution Medicines' current full-year earnings is ($3.49) per share. Wedbush also issued estimates for Revolution Medicines' Q4 2025 earnings at ($1.23) EPS, FY2025 earnings at ($3.41) EPS, FY2027 earnings at ($3.64) EPS, FY2028 earnings at ($3.10) EPS and FY2029 earnings at $1.97 EPS.

A number of other analysts have also recently weighed in on RVMD. HC Wainwright reaffirmed a "buy" rating and issued a $72.00 price target (down previously from $73.00) on shares of Revolution Medicines in a research report on Wednesday, May 14th. Needham & Company LLC reissued a "buy" rating and set a $57.00 price objective on shares of Revolution Medicines in a research report on Tuesday, June 24th. Stifel Nicolaus cut their price objective on Revolution Medicines from $78.00 to $64.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Guggenheim reissued a "buy" rating and set a $80.00 price objective on shares of Revolution Medicines in a research report on Wednesday, June 25th. Finally, Oppenheimer boosted their price objective on Revolution Medicines from $70.00 to $75.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $67.58.

Revolution Medicines Stock Down 0.3%

Shares of NASDAQ:RVMD traded down $0.12 on Friday, reaching $36.79. The company had a trading volume of 2,585,685 shares, compared to its average volume of 1,659,219. Revolution Medicines has a twelve month low of $29.17 and a twelve month high of $62.40. The stock has a 50-day moving average price of $39.61 and a 200 day moving average price of $39.86. The stock has a market capitalization of $6.85 billion, a P/E ratio of -9.20 and a beta of 1.10.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($1.13) earnings per share for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.01). During the same period in the prior year, the business earned ($0.70) earnings per share.

Hedge Funds Weigh In On Revolution Medicines

Several large investors have recently added to or reduced their stakes in RVMD. IFP Advisors Inc acquired a new position in Revolution Medicines in the 4th quarter valued at approximately $34,000. Banque Transatlantique SA acquired a new position in Revolution Medicines in the 1st quarter valued at approximately $42,000. Quarry LP acquired a new position in Revolution Medicines in the 1st quarter valued at approximately $50,000. Twin Tree Management LP acquired a new position in Revolution Medicines in the 1st quarter valued at approximately $58,000. Finally, Sterling Capital Management LLC raised its holdings in Revolution Medicines by 588.7% in the 4th quarter. Sterling Capital Management LLC now owns 1,956 shares of the company's stock valued at $86,000 after acquiring an additional 1,672 shares in the last quarter. Institutional investors and hedge funds own 94.34% of the company's stock.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.